Abemaciclib
Abemaciclib is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, a class of targeted cancer therapeutics indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2, also called ERBB2)-negative (HR+/HER2−) breast cancer.
Abemaciclib is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, a class of targeted cancer therapeutics indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2, also called ERBB2)-negative (HR+/HER2−) breast cancer. The drug represents a crucial first-line treatment component for advanced and metastatic breast cancer, where it is considered an essential part of standard-of-care management. By inhibiting CDK4/6-mediated cell cycle progression, abemaciclib prevents cancer cells from transitioning through the G1/S checkpoint, thereby suppressing tumor cell proliferation. The drug's mechanism is particularly effective when combined with endocrine therapy agents in hormone receptor-positive disease, reflecting the synergistic targeting of both growth signaling pathways and hormone receptor function. Recent evidence suggests potential utility beyond breast cancer, with CDK4/6 inhibitors including abemaciclib being investigated for application in other malignancies such as meningioma.
Where the papers sit
11 papers from the last 6 months study abemaciclib directly · updated from PubMed 6 Oct 2026
Study type 2 clinical trials · 5 observational · 1 human data · 1 preclinical · 2 unclassified
Themes one subject · 1 new direction
Those 11 are all about one subject.
-
Clinical Safety and Use
Abemaciclib treatment is being assessed through tolerability, adherence, patient experience, and survival, not efficacy alone. Diarrhea, neutropenia, hepatotoxicity, neuropsychiatric effects, and rare vascular or gastrointestinal events recur as clinically important risks, with comparisons to palbociclib and ribociclib highlighting divergent toxicity profiles. Rechallenge after progression and use with endocrine therapy remain pragmatic questions in hormone receptor-positive, HER2-negative breast cancer. Analytical work involving olaparib and exploratory discussion of meningioma broaden the agenda, but evidence remains heterogeneous and largely clinical.
Abemaciclib is presented as an immune-microenvironment modulator, not only a cell-cycle inhibitor
The metastatic hormone receptor-positive/HER2-negative breast-cancer single-cell study found that abemaciclib plus endocrine therapy altered immune-cell transcriptional states, including interferon-response programs, across tumor biopsies. This extends abemaciclib’s role beyond the cell-cycle arrest framework used elsewhere in the set to direct regulation of the tumor immune microenvironment, creating a distinct mechanistic direction 42126533May.
Papers
The 11 papers from the last 6 months that study abemaciclib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Clinical Safety and Use (11)
- Fatal drug-induced liver injury in the setting of abemaciclib therapy for metastatic breast cancer. BMJ case reports · 5 Oct 2026 PMID 42833841
- Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association. BMJ case reports · 28 Sept 2026 PMID 42805625
- Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study. Acta oncologica (Stockholm, Sweden) · 2 Sept 2026 PMID 42684120
- Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC-MS characterization of degradation products and in vitro performance evaluation. Journal of chromatographic science · 23 Jul 2026 PMID 42490602
- Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast cancer research and treatment · 20 Jul 2026 PMID 42474572
- A Case of Neutropenic Enterocolitis During Endocrine Therapy With Abemaciclib for Metastatic Breast Cancer. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379793
- Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. Pharmacoepidemiology and drug safety · 16 Jun 2026 PMID 42301003
- Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communication. Future oncology (London, England) · 22 May 2026 PMID 42169666
- Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor-Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 May 2026 PMID 42126533
- Divergent neuropsychiatric and systemic toxicity profiles of abemaciclib and palbociclib: a triangulation study integrating pharmacovigilance, genetic epidemiology, and multi-omics profiling. Naunyn-Schmiedeberg's archives of pharmacology · 6 May 2026 PMID 42091703
- Next-Generation Therapies for Meningioma: Overcoming Barriers and Expanding Treatment Options. Cancer investigation · 22 Apr 2026 PMID 42017452
By study type
Clinical trials (2)
- Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast cancer research and treatment · 20 Jul 2026 PMID 42474572
- Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communication. Future oncology (London, England) · 22 May 2026 PMID 42169666
Observational studies and case reports (5)
- Fatal drug-induced liver injury in the setting of abemaciclib therapy for metastatic breast cancer. BMJ case reports · 5 Oct 2026 PMID 42833841
- Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association. BMJ case reports · 28 Sept 2026 PMID 42805625
- Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study. Acta oncologica (Stockholm, Sweden) · 2 Sept 2026 PMID 42684120
- A Case of Neutropenic Enterocolitis During Endocrine Therapy With Abemaciclib for Metastatic Breast Cancer. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379793
- Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. Pharmacoepidemiology and drug safety · 16 Jun 2026 PMID 42301003
Human data, design not indexed (1)
- Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor-Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 May 2026 PMID 42126533
Preclinical: animal, cell and lab studies (1)
- Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC-MS characterization of degradation products and in vitro performance evaluation. Journal of chromatographic science · 23 Jul 2026 PMID 42490602
Unclassified: not yet indexed with MeSH (2)
- Divergent neuropsychiatric and systemic toxicity profiles of abemaciclib and palbociclib: a triangulation study integrating pharmacovigilance, genetic epidemiology, and multi-omics profiling. Naunyn-Schmiedeberg's archives of pharmacology · 6 May 2026 PMID 42091703
- Next-Generation Therapies for Meningioma: Overcoming Barriers and Expanding Treatment Options. Cancer investigation · 22 Apr 2026 PMID 42017452
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-07-24. Last written: 2026-09-04 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.